Information updates

ASCIA Guidelines - Vaccination of the egg-allergic individual - 2017 update

May 17, 2017

A revised version of the ASCIA Guidelines for vaccination of the egg-allergic individual is now available, which aims to provide updated recommendations for vaccination of egg-allergic individuals, consistent with international and current Australian and New Zealand Guidelines. The updated Guidelines are available open access on the ASCIA website: www.allergy.org.au/hp/papers/vaccination-of-the-egg-allergic-individual

The following is a summary of the revisions. 

Recommended

  • Based on prospective and retrospective studies of influenza vaccination in those with and without egg allergy (including egg anaphylaxis), the presence of egg allergy does not increase the risk of allergic reactions to the influenza vaccine.
  • The entire vaccine can be administered in community vaccination clinics (which may or may not have direct medical practitioner supervision) as a single dose followed by the recommended 15 (Australia) or 20 (New Zealand) minute waiting period.
  • In making this recommendation, we are aware that some guidelines (e.g. CDC 2017) recommend a longer waiting period of 30 minutes in those with past egg anaphylaxis and that occasionally allergic reactions to vaccination may commence later than 20-30 minutes after administration The immediate availability of medical practitioner care is recommended and staff should be familiar with the recognition and treatment of anaphylaxis.
  • In individuals who have had anaphylaxis following administration of the influenza vaccine itself, further vaccination should be avoided without specialist allergy assessment.
  • If there is significant parental or health professional anxiety, the vaccine may be administered in primary care settings with a longer waiting period of 30 minutes.

Not recommended

  • “Split dosing”
  • Allergy testing with the vaccine or to egg prior to administration
  • Ingestion of egg as a pre-condition to administering the vaccine (relevant in infants)
  • Vaccination in specific hospital-based vaccination clinics
  • Allergy specialist review before influenza vaccination unless anaphylaxis to the influenza vaccine itself has occurred previously

 

Content updated 17 May 2017

Mod ASCIA Member
Donate to AIFA
go to NAS website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.